trial · primary record
Vorinostat
Crohn's Disease
| Phase | Phase 1, Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 35 |
| Primary completion | 2035-06-30 |
| Primary endpoint | To evaluate the safety and tolerability of vorinostat in patients with moderate to severe CD as measured by the rate, frequency, and severity of adverse events (AEs) after 12 weeks of treatment. |
| Registry ID | NCT03167437 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-02T15:46:32.853Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT03167437
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.